Skip to content
Search

Latest Stories

MHRA appoints four non-executive directors to board

The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Dr Junaid Bajwa, Professor Graham Cooke, Dr Paul Goldsmith and Raj Long as four non-executive directors to the board for three years.

In addition, Haider Husain has been appointed as a non-voting associate non-executive director to the Board.


Their terms come into effect from today (September 1) to replace Dr Barbara Bannister MBE, Professor Bruce Campbell, Anne-Toni Rodgers and Professor David Webb CBE whose terms ended on August 31.

Welcoming the new members to the board, Stephen Lightfoot, chair of the MHRA Board said: “Their appointment brings a wealth of diverse experience and expertise that will add huge value to the strategic leadership of the Agency.”

Bajwa has a wide range of global digital health experience.

He is the chief medical scientist at Microsoft Research, a practising GP in London, non-executive director at University College London Hospitals NHS Foundation Trust, non-executive director of Nahdi Medical Corporation in Saudi Arabia and a visiting scientist at the Harvard School of Public Health in the US.

Cooke also has an extensive experience of international clinical research. He is NIHR professor of Infectious Diseases at Imperial College in London and leads the translational infection research within the NIHR Biomedical Research Centre.

He was also the principal investigator for the REACT study of Covid-19 home testing and chaired the WHO Committee on the Selection & Use of Essential Medicines.

The third non-executive director Goldsmith has a breadth of clinical, drug development, digital health and governance experience. He is a consultant neurologist and has held NHS clinical networks, vanguard and senate roles. He is also president, chief innovation officer and co-founder of Closed Loop Medicine Limited.

The fourth appointee Raj Long is a deputy director for safety and pharmacovigilance at the Gates Foundation and also supports the WHO Covid-19 vaccine manufacturing taskforce.

Associate non-executive director Haider Hussain is an experienced international healthcare IT business leader with a strong technology background.

He is the chief operating officer of Healthinnova Limited, a non-executive director of Milton Keynes University Hospital NHS Foundation Trust and is the panel chair for the Safe and Effective Use of AI in Healthcare at the British Standards Institute.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less